This is an international site for REVOLADE ® (eltrombopag) and is intended for health care professionals outside the US.

REVOLADE® (eltrombopag) offers the convenience of once-daily oral dosing in immune thrombocytopenia (ITP), severe aplastic anaemia (SAA), and chronic hepatitis C virus–associated …

REVOLADE® (eltrombopag) is the thrombopoietin receptor agonist (TPORA) that offers a proven and trusted response, including sustained response, in patients with chronic immune thrombocytopenia …

REVOLADE® (eltrombopag) enables patients with chronic hepatitis C virus–associated thrombocytopenia (HCVaT) to initiate antiviral therapy and to achieve sustained virologic response.

REVOLADE® (eltrombopag) has been proven in numerous clinical studies in adult and paediatric chronic immune thrombocytopenia (ITP), adult and paediatric severe aplastic anaemia (SAA), and …

REVOLADE® (eltrombopag) safety information for the treatment of adult and paediatric patients with immune thrombocytopenia (ITP), adult and paediatric patients with severe aplastic anaemia (SAA), …

REVOLADE® (eltrombopag), a thrombopoietin receptor agonist (TPO-RA), enables many patients with relapsed/refractory severe aplastic anaemia (SAA) to achieve a multilineage response and remain …

Revolade is indicated for the treatment of patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other …

REVOLADE® (eltrombopag) has a unique mechanism of action (MOA) that complements, rather than competes with endogenous thrombopoietin, stimulating an immunomodulatory response to promote …

REVOLADE® (eltrombopag) offers patients with chronic immune thrombocytopenia (ITP) effective therapy that helps to overcome some of the concerns they may have with other therapies such as …